Paul G. Richardson, MD, clinical program leader and director of clinical research, Jerome Lipper Multiple Myeloma Center; institute physician, Dana-Farber Cancer Institute; and RJ Corman Professor of Medicine at Harvard Medical School, discusses the next steps ​with the investigational cereblon E3 ligase modulator agent CC-92480 research in ​relapsed/refractory multiple myeloma.
Website: [ Ссылка ]
Twitter: [ Ссылка ]
Facebook: [ Ссылка ]
LinkedIn: [ Ссылка ]

свернуть